Moolec Science (NASDAQ: MLEC) CTO details stock option holdings in Form 3

Rhea-AI Filing Summary

Moolec Science SA Chief Technology Officer Paola Alexandra Diaz Dellavalle filed an initial ownership report showing direct holdings of share options over ordinary shares. The filing lists options to acquire 934, 933 and 933 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032 and 2033.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Diaz Dellavalle Paola Alexandra

(Last) (First) (Middle)

FRANCISCO DE MEDINA 1474

(Street)

MONTEVIDEO MONTEVIDEO 11600

(City) (State) (Zip)

URUGUAY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
02/06/2026

3. Issuer Name and Ticker or Trading Symbol
Moolec Science SA [ MLEC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Ordinary shares	02/06/2026	06/30/2031	Share Option	934	$7.14	D
Ordinary shares	06/30/2027	06/30/2032	Share Option	933	$7.14	D
Ordinary shares	06/30/2028	06/30/2033	Share Option	933	$7.14	D

Explanation of Responses:

	/s/ Paola Alexandra Diaz Dellavalle	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Moolec Science (MLEC) CTO report in this Form 3 filing?

The CTO reports initial beneficial ownership of share options over ordinary shares. The filing lists three option positions, each with a $7.14 exercise price and different expiration dates, providing a snapshot of her equity-based compensation holdings.

How many Moolec Science (MLEC) shares are covered by the CTO’s options?

The options cover 934, 933 and 933 underlying ordinary shares respectively. Each option position is reported separately, giving a total view of the number of Moolec Science shares that could be acquired through these option awards.

What is the exercise price of the Moolec Science (MLEC) CTO’s share options?

All reported share options have an exercise price of $7.14 per ordinary share. This price is the amount the CTO would pay per share when exercising the options, according to the positions disclosed in the filing data.

When do the Moolec Science (MLEC) CTO’s reported options expire?

The filing shows expiration dates in 2031, 2032 and 2033 for the three option positions. Each tranche of options has its own expiration date, defining the final year in which those options can be exercised.

Is this Moolec Science (MLEC) Form 3 a buy or sell transaction?

This Form 3 does not report share purchases or sales. It is an initial statement of beneficial ownership, listing existing share option holdings rather than new market transactions or changes in the CTO’s position in Moolec Science stock.